---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-090033"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2026-08-04T10:32:59+00:00"
generated_at: "2026-08-04T10:35:13.667094+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# IDEXX Laboratories Reports Q2 2026 Revenue of $1,217M and EPS of $4.27, Raises 2026 Outlook

## Summary
- Revenue grew 10% as reported and 9% organic; CAG Diagnostics recurring revenue grew 11% as reported and 10% organic.
- EPS of $4.27, up 18% as reported and 15% comparable; operating margin increased 140 bps as reported and 110 bps comparable.
- IDEXX inVue Dx installed base surpassed 9,000 instruments, with over 1,600 placements during Q2 2026.
- Narrows 2026 revenue guidance to $4,700M-$4,745M, up $5M at midpoint; raises EPS outlook to $14.69-$14.94.
- Updates 2026 organic revenue growth outlook to 8.5%-9.7% and CAG Diagnostics recurring revenue organic growth to 9.5%-10.7%.

## SEC filing metadata
- accession: 0001104659-26-090033
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2026-08-04T10:32:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465926090033/0001104659-26-090033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465926090033/tm2622041d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-090033
- JSON: https://secwatch.observer/filing/0001104659-26-090033.json
- Plain text: https://secwatch.observer/filing/0001104659-26-090033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.